Administration of Tranexamic Acid can affect the Intra-operative blood loss in Brain Tumor resection surgery

Effect of Tranexamic Acid on Intra-Operative Blood Loss in Brain Tumor Resection Surgery - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/073231

Enrollment

Registered

2024-09-02

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D496- Neoplasm of unspecified behavior of brain

Interventions

Intervention1: Effect Of Tranexamic Acid on intra-operative blood loss in Brain tumor resection Surgery: Patient’s in the study group will be administered Tranexamic acid (TXA) intravenously – 10 mg/

Eligibility

Inclusion criteria

Inclusion criteria: All patients diagnosed with brain tumor who will undergo tumor resection surgery after admission Age group 18 – 65 years Patient without any history of coagulopathy

Exclusion criteria

Exclusion criteria: Patient having hypersensitivity to Tranexamic acid Patients with known contraindications to antifibrinolytic agents Patients with thromboembolic events. Patients with abnormal liver function.

Design outcomes

Primary

Measure	Time frame
To study the effect of Tranexamic acid (TXA) on the intra-operative blood loss during tumor resection surgery. Timepoint: Base line post induction and continuous intra operative Blood Loss assessment at 30 minute interval	—

Countries

India

Contacts

Public ContactDr Deepshikha

heritage institute of medical sciences

abhinavheyar@gmail.com9988777074

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026